Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

NCT03894891 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03894891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03894891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
June 11, 2019
Completion date
December 16, 2022
Enrollment
6 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer